ArticleFrontiers in medicine2025
Increased risk of skin cancers in mucous membrane pemphigoid: a large-scale matched cohort study of 117 million US individuals.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Autoimmune Oral Mucosal Diseases in Older Patients: An Overview of Early Recognition and Management in the Primary Care Setting.Geriatrics (Basel, Switzerland) · 2026Review
- Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study.Lancet regional health. Americas · 2026Article
- Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review.Dermatology practical & conceptual · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mucous membrane pemphigoid (MMP) is an autoimmune disease affecting the oral mucosa, conjunctivae and other mucous membranes. The mainstay treatment options are local and systemic corticosteroids and immunomodulatory therapies. Current research on cancer risk in MMP is scarce and has yielded conflicting results. Methods: The aim of this study was to investigate the risk of developing skin cancer in patients with MMP by performing a large-scale, retrospective matched cohort study utilizing data from over 117 million US individuals. The risk of skin cancer in patients with MMP was observed within a 5-year follow-up period, along with three temporal difference analyses and stratification for disease severity. Results: MMP was associated with an increased risk of several types of skin cancers within the first 5 years of follow-up, particularly squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer. Stratification by disease severity showed significantly elevated risks in severe cases. Discussion: These findings underscore the importance of regular skin cancer screening and risk-based monitoring in MMP patients, particularly those with severe disease. Integrating dermatologic surveillance into routine care could facilitate early detection and timely intervention. Additionally, these results highlight the need for further research into cancer risks in other autoimmune blistering diseases, helping to refine long-term management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.